PHAT - Phathom Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
71,441
71,441
72,338
98,148
99,271
Selling general and administrative
100,999
100,999
62,742
27,517
6,944
Total operating expenses
172,440
172,440
135,080
125,665
106,215
Operating income or loss
-172,440
-172,440
-135,080
-125,665
-106,215
Interest expense
27,305
27,305
6,788
4,581
4,177
Total other income/expenses net
-110
-110
-2,056
87
-145,828
Income before tax
-197,723
-197,723
-143,883
-129,068
-255,131
Income from continuing operations
-197,723
-197,723
-143,883
-129,068
-255,131
Net income
-197,723
-197,723
-143,883
-129,068
-255,131
Net income available to common shareholders
-197,723
-197,723
-143,883
-129,068
-255,131
Basic EPS
-
-5.05
-3.89
-3.88
-22.45
Diluted EPS
-
-5.05
-3.89
-3.88
-22.45
Basic average shares
-
39,118
37,003
33,228
11,367
Diluted average shares
-
39,118
37,003
33,228
11,367
EBITDA
-
-170,418
-137,095
-124,487
-250,954